head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
Published 6 years ago • 1.7K plays • Length 2:13Download video MP4
Download video MP3
Similar videos
-
0:42
enzalutamide in the non-metastatic setting for crpc
-
1:34
dr. chi on abiraterone versus enzalutamide for metastatic castration-resistant prostate cancer
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
5:16
enzamet: enzalutamide for metastatic prostate cancer
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
8:12
the use of abiraterone and enzalutamide against crpc
-
2:45
trial of lhrha, abiraterone and enzalutamide: filling an unmet need in prostate cancer therapy
-
0:59
dr. crawford on abiraterone versus enzalutamide in prostate cancer
-
2:50
prosper: enzalutamide vs. placebo for nmcrpc
-
4:12
ocuu-crpc trial: enzalutamide vs. flutamide for crpc after bicalutamide
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
25:31
management of advanced hormone-sensitive and castration-resistant prostate cancer
-
6:42
titan trial
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
-
3:14
treatment with abiraterone acetate without steroids in mcrpc
-
0:39
stereotactic body rt in patients with oligometastatic crpc undergoing 1l treatment with abiraterone
-
1:55
awaiting key results for enzalutamide and apalutamide in nmcrpc
-
4:34
card: cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer